FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 332:1317-1322 May 18, 1995 Number 20 Next

	Full Text PDF Letters Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background In a previous open-label study of hydroxyurea therapy, the synthesis of fetal hemoglobin increased in most patients with sickle cell anemia, with only mild myelotoxicity. By inhibiting sickling, increased levels of fetal hemoglobin might decrease the frequency of painful crises.

Methods In a double-blind, randomized clinical trial, we tested the efficacy of hydroxyurea in reducing the frequency of painful crises in adults with a history of three or more such crises per year. The trial was stopped after a mean follow-up of 21 months.

Results Among 148 men and 151 women studied at 21 clinics, the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P<0.001). The median times to the first crisis (3.0 vs. 1.5 months, P = 0.01) and the second crisis (8.8 vs. 4.6 months, P<0.001) were longer with hydroxyurea treatment. Fewer patients assigned to hydroxyurea had chest syndrome (25 vs. 51, P<0.001), and fewer underwent transfusions (48 vs. 73, P = 0.001). At the end of the study, the doses of hydroxyurea ranged from 0 to 35 mg per kilogram of body weight per day. Treatment with hydroxyurea did not cause any important adverse effects.

Conclusions Hydroxyurea therapy can ameliorate the clinical course of sickle cell anemia in some adults with three or more painful crises per year. Maximal tolerated doses of hydroxyurea may not be necessary to achieve a therapeutic effect. The beneficial effects of hydroxyurea do not become manifest for several months, and its use must be carefully monitored. The long-term safety of hydroxyurea in patients with sickle cell anemia is uncertain.

Source Information

From the Johns Hopkins University School of Medicine, Baltimore (S.C., R.D.M., G.J.D., S.V.E.); the Maryland Medical Research Institute, Baltimore (M.L.T., F.B.B., R.P.M.); and the National Heart, Lung, and Blood Institute, Bethesda, Md. (D.R.B.).

Address reprint requests to Dr. Charache at B121 Meyer Bldg., Johns Hopkins Hospital, 600 N. Wolfe St., Baltimore, MD 21287-7061.

Full Text of this Article

Related Letters:

Hydroxyurea and Sickle Cell Crisis
Ho P. T.C., Murgo A. J., Silver R. T., Charache S., Dover G. J., Moore R. D., Terrin M. L.
Extract | Full Text  
N Engl J Med 1995; 333:1008-1009, Oct 12, 1995. Correspondence

Hydroxyurea in Sickle Cell Disease
Schechter A. N., Rodgers G. P., Adams-Graves P., Heltsley C., Deitcher S.
Extract | Full Text  
N Engl J Med 1996; 334:333-334, Feb 1, 1996. Correspondence

Pitfalls of Genetic Testing
Stern H. J., Maddalena A., Schulman J. D., Foulkes W. D., Bunn H. F., Stossel T. P., Forget B. G., Stamatoyannopoulos G., Weatherall D. J., Hubbard R., Lewontin R.C.
Extract | Full Text  
N Engl J Med 1996; 335:1235-1237, Oct 17, 1996. Correspondence

This article has been cited by other articles:

• Adegbola, M. A. (2009). Can Heterogeneity of Chronic Sickle-Cell Disease Pain Be Explained by Genomics? A Literature Review. Biol Res Nurs 11: 81-97 [Abstract]  
• Pais, E., Cambridge, J. S., Johnson, C. S., Meiselman, H. J., Fisher, T. C., Alexy, T. (2009). A Novel High-Throughput Screening Assay for Sickle Cell Disease Drug Discovery. J Biomol Screen 14: 330-336 [Abstract]  
• Dick, M C (2008). Standards for the management of sickle cell disease in children. EDUCATION AND PRACTICE 93: 169-176 [Abstract] [Full Text]  
• Ghatpande, S. S., Choudhary, P. K., Quinn, C. T., Goodman, S. R. (2008). Pharmaco-Proteomic Study of Hydroxyurea-Induced Modifications in the Sickle Red Blood Cell Membrane Proteome. Exp. Biol. Med. 233: 1510-1517 [Abstract] [Full Text]  
• Strouse, J. J., Lanzkron, S., Beach, M. C., Haywood, C., Park, H., Witkop, C., Wilson, R. F., Bass, E. B., Segal, J. B. (2008). Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children. Pediatrics 122: 1332-1342 [Abstract] [Full Text]  
• Mueller, B. U. (2008). When Should Hydroxyurea Be Used for Children With Sickle Cell Disease?. Pediatrics 122: 1365-1366 [Full Text]  
• Schechter, A. N. (2008). Hemoglobin research and the origins of molecular medicine. Blood 112: 3927-3938 [Abstract] [Full Text]  
• Zennadi, R., Chien, A., Xu, K., Batchvarova, M., Telen, M. J. (2008). Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood 112: 3474-3483 [Abstract] [Full Text]  
• Montalembert, M. d. (2008). Management of sickle cell disease. BMJ 337: a1397-a1397 [Full Text]  
• Roach, E. S., Golomb, M. R., Adams, R., Biller, J., Daniels, S., deVeber, G., Ferriero, D., Jones, B. V., Kirkham, F. J., Scott, R. M., Smith, E. R. (2008). Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 39: 2644-2691 [Abstract] [Full Text]  
• Berthaut, I., Guignedoux, G., Kirsch-Noir, F., de Larouziere, V., Ravel, C., Bachir, D., Galacteros, F., Ancel, P.-Y., Kunstmann, J.-M., Levy, L., Jouannet, P., Girot, R., Mandelbaum, J. (2008). Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. haematol 93: 988-993 [Abstract] [Full Text]  
• Lanzkron, S., Strouse, J. J., Wilson, R., Beach, M. C., Haywood, C., Park, H., Witkop, C., Bass, E. B., Segal, J. B. (2008). Systematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease. ANN INTERN MED 148: 939-955 [Abstract] [Full Text]  
• Yin, D., Wang, X., Konda, B. M., Ong, J. M., Hu, J., Sacapano, M. R., Ko, M. K., Espinoza, A. J., Irvin, D. K., Shu, Y., Black, K. L. (2008). Increase in Brain Tumor Permeability in Glioma-Bearing Rats with Nitric Oxide Donors. Clin. Cancer Res. 14: 4002-4009 [Abstract] [Full Text]  
• Ataga, K. I., Smith, W. R., De Castro, L. M., Swerdlow, P., Saunthararajah, Y., Castro, O., Vichinsky, E., Kutlar, A., Orringer, E. P., Rigdon, G. C., Stocker, J. W., for the ICA-17043-05 Investigators, (2008). Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 111: 3991-3997 [Abstract] [Full Text]  
• Johnson, C., Telen, M. J. (2008). Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease. haematol 93: 481-485 [Full Text]  
• Odievre, M.-H., Bony, V., Benkerrou, M., Lapoumeroulie, C., Alberti, C., Ducrocq, R., Jacqz-Aigrain, E., Elion, J., Cartron, J.-P. (2008). Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. haematol 93: 502-510 [Abstract] [Full Text]  
• Canalli, A. A., Franco-Penteado, C. F., Saad, S. T.O., Conran, N., Costa, F. F. (2008). Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. haematol 93: 605-609 [Abstract] [Full Text]  
• Platt, O. S. (2008). Hydroxyurea for the Treatment of Sickle Cell Anemia. NEJM 358: 1362-1369 [Full Text]  
• Solomon, L. R. (2008). Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void. Blood 111: 997-1003 [Abstract] [Full Text]  
• Cokic, V. P., Andric, S. A., Stojilkovic, S. S., Noguchi, C. T., Schechter, A. N. (2008). Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood 111: 1117-1123 [Abstract] [Full Text]  
• Smith, W. R., Penberthy, L. T., Bovbjerg, V. E., McClish, D. K., Roberts, J. D., Dahman, B., Aisiku, I. P., Levenson, J. L., Roseff, S. D. (2008). Daily Assessment of Pain in Adults with Sickle Cell Disease. ANN INTERN MED 148: 94-101 [Abstract] [Full Text]  
• Kato, G. J. (2008). Novel Small Molecule Therapeutics for Sickle Cell Disease: Nitric Oxide, Carbon Monoxide, Nitrite, and Apolipoprotein A-I. ASH Education Book 2008: 186-192 [Abstract] [Full Text]  
• Benjamin, L. (2008). Pain Management in Sickle Cell Disease: Palliative Care Begins at Birth?. ASH Education Book 2008: 466-474 [Abstract] [Full Text]  
• Haynes, J. Jr., Obiako, B., Hester, R. B., Baliga, B. S., Stevens, T. (2008). Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium. Am. J. Physiol. Heart Circ. Physiol. 294: H379-H385 [Abstract] [Full Text]  
• Banerjee, A., Chakrabarty, S. B., Karmakar, S. R., Chakrabarty, A., Biswas, S. J., Haque, S., Das, D., Paul, S., Mandal, B., Naoual, B., Belon, P., Khuda-Bukhsh, A. R. (2007). Can Homeopathy Bring Additional Benefits to Thalassemic Patients on Hydroxyurea Therapy? Encouraging Results of a Preliminary Study. Evid Based Complement Alternat Med 0: nem161v1-nem161 [Abstract] [Full Text]  
• Aerbajinai, W., Zhu, J., Gao, Z., Chin, K., Rodgers, G. P. (2007). Thalidomide induces {gamma}-globin gene expression through increased reactive oxygen species mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 110: 2864-2871 [Abstract] [Full Text]  
• Bernaudin, F., Socie, G., Kuentz, M., Chevret, S., Duval, M., Bertrand, Y., Vannier, J.-P., Yakouben, K., Thuret, I., Bordigoni, P., Fischer, A., Lutz, P., Stephan, J.-L., Dhedin, N., Plouvier, E., Margueritte, G., Bories, D., Verlhac, S., Esperou, H., Coic, L., Vernant, J.-P., Gluckman, E., for the Societe Francaise de Greffe de Moelle et d, (2007). Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood 110: 2749-2756 [Abstract] [Full Text]  
• He, Z., Russell, J. E. (2007). Dynamic posttranscriptional regulation of {epsilon}-globin gene expression in vivo. Blood 109: 795-801 [Abstract] [Full Text]  
• Telen, M. J. (2007). Role of Adhesion Molecules and Vascular Endothelium in the Pathogenesis of Sickle Cell Disease. ASH Education Book 2007: 84-90 [Abstract] [Full Text]  
• DeBaun, M. R., Field, J. J. (2007). Limitations of Clinical Trials in Sickle Cell Disease: A Case Study of the Multi-center Study of Hydroxyurea (MSH) Trial and the Stroke Prevention (STOP) Trial. ASH Education Book 2007: 482-488 [Abstract] [Full Text]  
• Buchanan, G. R., Kahn, M. J. (2007). Hemolytic anemias. ASH-SAP 2007: 102-142 [Full Text]  
• Quinn, C. T., Shull, E. P., Ahmad, N., Lee, N. J., Rogers, Z. R., Buchanan, G. R. (2007). Prognostic significance of early vaso-occlusive complications in children with sickle cell anemia. Blood 109: 40-45 [Abstract] [Full Text]  
• Franco, R. S., Yasin, Z., Palascak, M. B., Ciraolo, P., Joiner, C. H., Rucknagel, D. L. (2006). The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood 108: 1073-1076 [Abstract] [Full Text]  
• Machado, R. F., Anthi, A., Steinberg, M. H., Bonds, D., Sachdev, V., Kato, G. J., Taveira-DaSilva, A. M., Ballas, S. K., Blackwelder, W., Xu, X., Hunter, L., Barton, B., Waclawiw, M., Castro, O., Gladwin, M. T., for the MSH Investigators, (2006). N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease.. JAMA 296: 310-318 [Abstract] [Full Text]  
• Cokic, V. P., Beleslin-Cokic, B. B., Tomic, M., Stojilkovic, S. S., Noguchi, C. T., Schechter, A. N. (2006). Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood 108: 184-191 [Abstract] [Full Text]  
• Goldstein, L. B., Adams, R., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C. D., Culebras, A., DeGraba, T. J., Gorelick, P. B., Guyton, J. R., Hart, R. G., Howard, G., Kelly-Hayes, M., Nixon, J.V., Sacco, R. L. (2006). Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.. Circulation 113: e873-e923 [Abstract] [Full Text]  
• Goldstein, L. B., Adams, R., Alberts, M. J., Appel, L. J., Brass, L. M., Bushnell, C. D., Culebras, A., DeGraba, T. J., Gorelick, P. B., Guyton, J. R., Hart, R. G., Howard, G., Kelly-Hayes, M., Nixon, J.V., Sacco, R. L. (2006). Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline.. Stroke 37: 1583-1633 [Abstract] [Full Text]  
• Attar, E. C., Hasserjian, R. P. (2006). Case 14-2006 -- a 25-year-old woman with anemia and iron overload.. NEJM 354: 2047-2056 [Full Text]  
• Smith, L. A., Oyeku, S. O., Homer, C., Zuckerman, B. (2006). Sickle Cell Disease: A Question of Equity and Quality. Pediatrics 117: 1763-1770 [Abstract] [Full Text]  
• Villella, A. D. (2006). Hydroxyurea Therapy for Infants with Sickle Cell Anemia. AAP Grand Rounds 15: 39-40 [Full Text]  
• Platt, O. S. (2006). Prevention and Management of Stroke in Sickle Cell Anemia. ASH Education Book 2006: 54-57 [Abstract] [Full Text]  
• Fathallah, H., Atweh, G. F. (2006). Induction of Fetal Hemoglobin in the Treatment of Sickle Cell Disease. ASH Education Book 2006: 58-62 [Abstract] [Full Text]  
• (2005). Additional Information. JAMA 294: E1-E3 [Full Text]  
• Tang, D. C., Zhu, J., Liu, W., Chin, K., Sun, J., Chen, L., Hanover, J. A., Rodgers, G. P. (2005). The hydroxyurea-induced small GTP-binding protein SAR modulates {gamma}-globin gene expression in human erythroid cells. Blood 106: 3256-3263 [Abstract] [Full Text]  
• Dover, G. J. (2005). Hydroxyurea therapy in SS children. Blood 106: 2228-2228 [Full Text]  
• Hankins, J. S., Ware, R. E., Rogers, Z. R., Wynn, L. W., Lane, P. A., Scott, J. P., Wang, W. C. (2005). Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 106: 2269-2275 [Abstract] [Full Text]  
• Pattillo, R. E., Gladden, L. B. (2005). Red blood cell lactate transport in sickle disease and sickle cell trait. J. Appl. Physiol. 99: 822-827 [Abstract] [Full Text]  
• Villella, A. D. (2005). Mortality in Sickle Cell Patients on Hydroxyurea Therapy. AAP Grand Rounds 14: 14-15 [Full Text]  
• Yan, J.-H., Ataga, K., Kaul, S., Olson, J. S., Grasela, D. M., Gothelf, S., Kutlar, A., Orringer, E. (2005). The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease. J Clin Pharmacol 45: 434-445 [Abstract] [Full Text]  
• Coller, B. S. (2005). Leukocytosis and Ischemic Vascular Disease Morbidity and Mortality: Is It Time to Intervene?. Arterioscler. Thromb. Vasc. Bio. 25: 658-670 [Abstract] [Full Text]  
• Gulbis, B., Haberman, D., Dufour, D., Christophe, C., Vermylen, C., Kagambega, F., Corazza, F., Devalck, C., Dresse, M.-F., Hunninck, K., Klein, A., Quoc Le, P., Loop, M., Maes, P., Philippet, P., Sariban, E., Van Geet, C., Ferster, A. (2005). Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood 105: 2685-2690 [Abstract] [Full Text]  
• Weinberg, R. S., Ji, X., Sutton, M., Perrine, S., Galperin, Y., Li, Q., Liebhaber, S. A., Stamatoyannopoulos, G., Atweh, G. F. (2005). Butyrate increases the efficiency of translation of {gamma}-globin mRNA. Blood 105: 1807-1809 [Abstract] [Full Text]  
• Steinberg, M. H. (2005). Sickle cell disease and hydroxyurea: the good, the bad, and the future. Blood 105: 441-441 [Full Text]  
• Bakanay, S. M., Dainer, E., Clair, B., Adekile, A., Daitch, L., Wells, L., Holley, L., Smith, D., Kutlar, A. (2005). Mortality in sickle cell patients on hydroxyurea therapy. Blood 105: 545-547 [Abstract] [Full Text]  
• Lew, V. L., Bookchin, R. M. (2005). Ion Transport Pathology in the Mechanism of Sickle Cell Dehydration. Physiol. Rev. 85: 179-200 [Abstract] [Full Text]  
• Lottenberg, R., Hassell, K. L. (2005). An Evidence-Based Approach to the Treatment of Adults with Sickle Cell Disease. ASH Education Book 2005: 58-65 [Abstract] [Full Text]  
• Quinn, C. T., Rogers, Z. R., Buchanan, G. R. (2004). Survival of children with sickle cell disease. Blood 103: 4023-4027 [Abstract] [Full Text]  
• Haynes, J. Jr, Baliga, B. S., Obiako, B., Ofori-Acquah, S., Pace, B. (2004). Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway. Blood 103: 3945-3950 [Abstract] [Full Text]  
• de Montalembert, M, Maunoury, C, Acar, P, Brousse, V, Sidi, D, Lenoir, G (2004). Myocardial ischaemia in children with sickle cell disease. Arch. Dis. Child. 89: 359-362 [Abstract] [Full Text]  
• Zimmerman, S. A., Schultz, W. H., Davis, J. S., Pickens, C. V., Mortier, N. A., Howard, T. A., Ware, R. E. (2004). Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103: 2039-2045 [Abstract] [Full Text]  
• Cao, H., Stamatoyannopoulos, G., Jung, M. (2004). Induction of human {gamma} globin gene expression by histone deacetylase inhibitors. Blood 103: 701-709 [Abstract] [Full Text]  
• Tong, P. C., Lee, K.-F., So, W.-Y., Ng, M. H., Chan, W.-B., Lo, M. K., Chan, N. N., Chan, J. C. (2004). White Blood Cell Count Is Associated With Macro- and Microvascular Complications in Chinese Patients With Type 2 Diabetes. Diabetes Care 27: 216-222 [Abstract] [Full Text]  
• Atweh, G. F. (2003). Hypomethylation therapy for hemoglobin disorders is back at center stage. Blood 102: 3855-3856 [Full Text]  
• Saunthararajah, Y., Hillery, C. A., Lavelle, D., Molokie, R., Dorn, L., Bressler, L., Gavazova, S., Chen, Y.-H., Hoffman, R., DeSimone, J. (2003). Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 102: 3865-3870 [Abstract] [Full Text]  
• Claster, S., Vichinsky, E. P (2003). Managing sickle cell disease. BMJ 327: 1151-1155 [Full Text]  
• Fibach, E., Bianchi, N., Borgatti, M., Prus, E., Gambari, R. (2003). Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells. Blood 102: 1276-1281 [Abstract] [Full Text]  
• Selvaraj, S. K., Giri, R. K., Perelman, N., Johnson, C., Malik, P., Kalra, V. K. (2003). Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 102: 1515-1524 [Abstract] [Full Text]  
• Bradai, M., Abad, M. T., Pissard, S., Lamraoui, F., Skopinski, L., de Montalembert, M. (2003). Hydroxyurea can eliminate transfusion requirements in children with severe {beta}-thalassemia. Blood 102: 1529-1530 [Abstract] [Full Text]  
• Lee, D. A., Mueller, B. U. (2003). Long-term Use of Hydroxyurea for Sickle Cell Anemia. JAMA 290: 753-754 [Full Text]  
• Mak, V, Davies, S C (2003). The pulmonary physician in critical care * Illustrative case 6: Acute chest syndrome of sickle cell anaemia. Thorax 58: 726-728 [Full Text]  
• Siddiqui, A K, Ahmed, S (2003). Pulmonary manifestations of sickle cell disease. Postgrad. Med. J. 79: 384-390 [Abstract] [Full Text]  
• Steinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., Varma, M., Ramirez, G., Adler, B., Smith, W., Carlos, T., Ataga, K., DeCastro, L., Bigelow, C., Saunthararajah, Y., Telfer, M., Vichinsky, E., Claster, S., Shurin, S., Bridges, K., Waclawiw, M., Bonds, D., Terrin, M. (2003). Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment. JAMA 289: 1645-1651 [Abstract] [Full Text]  
• Weiner, D. L., Brugnara, C. (2003). Hydroxyurea and Sickle Cell Disease: A Chance for Every Patient. JAMA 289: 1692-1694 [Full Text]  
• Gabbianelli, M., Testa, U., Massa, A., Morsilli, O., Saulle, E., Sposi, N. M., Petrucci, E., Mariani, G., Peschle, C. (2003). HbF reactivation in sibling BFU-E colonies: synergistic interaction of kit ligand with low-dose dexamethasone. Blood 101: 2826-2832 [Abstract] [Full Text]  
• Atweh, G. F., DeSimone, J., Saunthararajah, Y., Fathallah, H., Weinberg, R. S., Nagel, R. L., Fabry, M. E., Adams, R. J. (2003). Hemoglobinopathies. ASH Education Book 2003: 14-39 [Abstract] [Full Text]  
• Helton, K. J., Wang, W. C., Wynn, L. W., Khan, R. B., Steen, R. G. (2002). The Effect of Hydroxyurea on Vasculopathy in a Child with Sickle Cell Disease. Am. J. Neuroradiol. 23: 1692-1696 [Abstract] [Full Text]  
• He, Z., Russell, J. E. (2002). A human embryonic hemoglobin inhibits Hb S polymerization in vitro and restores a normal phenotype to mouse models of sickle cell disease. Proc. Natl. Acad. Sci. USA 99: 10635-10640 [Abstract] [Full Text]  
• Salzman, S. H. (2002). Does Splinting From Thoracic Bone Ischemia and Infarction Contribute to the Acute Chest Syndrome in Sickle Cell Disease?. Chest 122: 6-9 [Full Text]  
• Venigalla, P., Motwani, B., Nallari, A., Allen, S., Agarwal, M., Alva, M., Westerman, M., Feldman, L. (2002). A patient on hydroxyurea for sickle cell disease who developed an opportunistic infection. Blood 100: 363-364 [Full Text]  
• DeSimone, J., Koshy, M., Dorn, L., Lavelle, D., Bressler, L., Molokie, R., Talischy, N. (2002). Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 99: 3905-3908 [Abstract] [Full Text]  
• Anie, K A, Steptoe, A, Ball, S, Dick, M, Smalling, B M (2002). Coping and health service utilisation in a UK study of paediatric sickle cell pain. Arch. Dis. Child. 86: 325-329 [Abstract] [Full Text]  
• Benkerrou, M., Delarche, C., Brahimi, L., Fay, M., Vilmer, E., Elion, J., Gougerot-Pocidalo, M.-A., Elbim, C. (2002). Hydroxyurea corrects the dysregulated L-selectin expression and increased H2O2 production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 99: 2297-2303 [Abstract] [Full Text]  
• Section on Hematology/Oncology and Committee on Ge, (2002). Health Supervision for Children with Sickle Cell Disease. Pediatrics 109: 526-535 [Abstract] [Full Text]  
• Kean, L. S., Durham, M. M., Adams, A. B., Hsu, L. L., Perry, J. R., Dillehay, D., Pearson, T. C., Waller, E. K., Larsen, C. P., Archer, D. R. (2002). A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation. Blood 99: 1840-1849 [Abstract] [Full Text]  
• Catlett, J. P., Alving, B. M. (2002). Update in Hematology. ANN INTERN MED 136: 136-143 [Full Text]  
• Walters, M. C., Nienhuis, A. W., Vichinsky, E. (2002). Novel Therapeutic Approaches in Sickle Cell Disease. ASH Education Book 2002: 10-34 [Abstract] [Full Text]  
• Ware, R. E., Eggleston, B., Redding-Lallinger, R., Wang, W. C., Smith-Whitley, K., Daeschner, C., Gee, B., Styles, L. A., Helms, R. W., Kinney, T. R., Ohene-Frempong, K. (2002). Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 99: 10-14 [Abstract] [Full Text]  
• MINTER, K. R., GLADWIN, M. T. (2001). Pulmonary Complications of Sickle Cell Anemia . A Need for Increased Recognition, Treatment, and Research. Am. J. Respir. Crit. Care Med. 164: 2016-2019 [Full Text]  
• Orringer, E. P., Casella, J. F., Ataga, K. I., Koshy, M., Adams-Graves, P., Luchtman-Jones, L., Wun, T., Watanabe, M., Shafer, F., Kutlar, A., Abboud, M., Steinberg, M., Adler, B., Swerdlow, P., Terregino, C., Saccente, S., Files, B., Ballas, S., Brown, R., Wojtowicz-Praga, S., Grindel, J. M. (2001). Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease: A Randomized Controlled Trial. JAMA 286: 2099-2106 [Abstract] [Full Text]  
• Nagel, R. L. (2001). The Challenge of Painful Crisis in Sickle Cell Disease. JAMA 286: 2152-2153 [Full Text]  
• Park, J.-I., Choi, H.-S., Jeong, J.-S., Han, J.-Y., Kim, I.-H. (2001). Involvement of p38 Kinase in Hydroxyurea-induced Differentiation of K562 Cells. Cell Growth Differ. 12: 481-486 [Abstract] [Full Text]  
• Lee, K., Gane, P., Roudot-Thoraval, F., Godeau, B., Bachir, D., Bernaudin, F., Cartron, J.-P., Galacteros, F., Bierling, P. (2001). The nonexpression of CD36 on reticulocytes and mature red blood cells does not modify the clinical course of patients with sickle cell anemia. Blood 98: 966-971 [Abstract] [Full Text]  
• Weinberg, A. (2001). In Vitro Hydroxyurea Decreases Th1 Cell-Mediated Immunity. CVI 8: 702-705 [Abstract] [Full Text]  
• Joiner, C. H., Jiang, M., Claussen, W. J., Roszell, N. J., Yasin, Z., Franco, R. S. (2001). Dipyridamole inhibits sickling-induced cation fluxes in sickle red blood cells. Blood 97: 3976-3983 [Abstract] [Full Text]  
• Ferster, A., Tahriri, P., Vermylen, C., Sturbois, G., Corazza, F., Fondu, P., Devalck, C., Dresse, M. F., Feremans, W., Hunninck, K., Toppet, M., Philippet, P., Van Geet, C., Sariban, E. (2001). Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 97: 3628-3632 [Abstract] [Full Text]  
• Setty, B. N. Y., Kulkarni, S., Dampier, C. D., Stuart, M. J. (2001). Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion. Blood 97: 2568-2573 [Abstract] [Full Text]  
• Adams, R. J. (2001). Stroke Prevention and Treatment in Sickle Cell Disease. Arch Neurol 58: 565-568 [Full Text]  
• Chaine, B., Neonato, M.-G., Girot, R., Aractingi, S. (2001). Cutaneous Adverse Reactions to Hydroxyurea in Patients With Sickle Cell Disease. Arch Dermatol 137: 467-470 [Abstract] [Full Text]  
• Schmugge, M., Frischknecht, H., Yonekawa, Y., Baumgartner, R. W., Boltshauser, E., Humbert, J. (2001). Stroke in hemoglobin (SD) sickle cell disease with moyamoya: successful hydroxyurea treatment after cerebrovascular bypass surgery. Blood 97: 2165-2167 [Abstract] [Full Text]